Abivax S.A.

• Leading gastroenterologist Dr. David Rubin will provide expert insights on the ulcerative colitis treatment landscape and discuss Abivax's ABTECT Phase 3 trial of obefazimod. • The virtual event, scheduled for March 17, 2025, will explore obefazimod's potential to address unmet medical needs in ulcerative colitis treatment. • Attendees will have the opportunity to engage with Dr. Rubin and Abivax's management team during a live Q&A session following the presentation.

• French biotech Abivax reports significant breakthrough as their drug ABX464 achieves up to 52% reduction in HIV DNA levels during 28-day treatment in phase 2a trial. • Extended 12-week study with lower dosage demonstrates HIV DNA reduction up to 85% in some patients, marking first evidence of ABX464's ability to impact both blood and rectal tissue viral reservoirs. • The treatment shows potential for complete virus elimination and long-term viral load control, with favorable safety profile supporting extended dosing regimens.

• Abivax's Phase 3 trials for obefazimod in ulcerative colitis are progressing well, with over 80% enrollment, suggesting timely completion and results expected in Q3 2025. • Strategic trial design, including an 8-week primary endpoint and exclusion of certain immunomodulators, aims to minimize placebo response and maximize success potential. • Analysts maintain a Buy rating for Abivax, supported by the company's solid financial position and the potential of obefazimod as an effective treatment option. • Patient characteristics in the Phase 3 trials are consistent with previous studies, enhancing confidence in replicating successful Phase 2b results.

Abivax's ABTECT Phase 3 trial for obefazimod in ulcerative colitis has reached 82% enrollment, with 1,003 of 1,224 participants now recruited.

• Abivax has initiated its Phase 2b ENHANCE-CD trial, with the first patient enrolled to evaluate obefazimod in Crohn's disease. • The trial is a multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of once-daily obefazimod in adults. • The study includes a 12-week induction phase, a 40-week maintenance phase, and a 48-week extension phase to assess long-term safety. • Obefazimod, an oral small molecule, aims to stabilize the immune response by enhancing miR-124 expression, offering a convenient treatment option.

• Abivax's Phase 3 ABTECT trial, evaluating obefazimod for ulcerative colitis, has surpassed 600 patients enrolled, marking a significant milestone. • The trial is on track to achieve full enrollment in early Q1 2025, reinforcing the company's timeline for this pivotal study. • Baseline characteristics of participants align with observations from the Phase 2b trial, suggesting consistency in patient population. • Obefazimod, an oral small molecule, aims to enhance miR-124 expression and is also planned for a Phase 2b trial in Crohn's disease.